Vitamin D pathway gene variants and prostate cancer risk
- PMID: 19454612
- PMCID: PMC2743676
- DOI: 10.1158/1055-9965.EPI-09-0113
Vitamin D pathway gene variants and prostate cancer risk
Abstract
Vitamin D has antiproliferative, antiangiogenic, and apoptotic properties. There is some evidence supporting an association between vitamin D-related gene variants and prostate cancer risk. We report results from this population-based case-control study of genes encoding for the vitamin D receptor (VDR), the vitamin D activating enzyme 1-alpha-hydroxylase (CYP27B1), and deactivating enzyme 24-hydroxylase (CYP24A1). Forty-eight tagging single nucleotide polymorphisms (tagSNP) were analyzed in 827 incident prostate cancer cases diagnosed from 2002 to 2005, and in 787 age-matched controls. Contrary to some earlier studies, we found no strong evidence of altered risk of developing prostate cancer overall or within clinical measures of tumor aggressiveness for any of the tagSNPs when they were assessed individually or in haplotypes.
References
-
- Holick MF. Vitamin D: Its Role in Cancer Prevention and Treatment. Prog Biophys Mol Biol. 2006;92:49–59. - PubMed
-
- Krishnan AV, Peehl DM, Feldman D. Inhibition of Prostate Cancer Growth by Vitamin D: Regulation of Target Gene Expression. Journal of Cellular Biochemistry. 2003;88:363–71. - PubMed
-
- Schwartz GG, Hanchette CL. UV, Latitude, and Spatial Trends in Prostate Cancer Mortality: All Sunlight Is Not the Same (United States) Cancer Causes & Control. 2006;17:1091–101. - PubMed
-
- Giovannucci E. Vitamin D Status and Cancer Incidence and Mortality. Adv Exp Med Biol. 2008;624:31–42. - PubMed
-
- Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-Hydroxyvitamin D-1alpha-Hydroxylase and Its Implication in Prostate Cancer. J Cell Biochem. 2003;88:315–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
